Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Multicenter, Randomized, Open-label, Active-controlled, Single/Multiple-dose, Dose-finding, Clinical Study of GenSci134 in Children With Idiopathic Short Stature
Conditions
Interventions
GenSci134 Injection
Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
Locations
1
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Start Date
March 6, 2026
Primary Completion Date
July 18, 2028
Completion Date
December 31, 2028
Last Updated
March 4, 2026
NCT06382155
NCT06309979
NCT01604395
NCT05894876
NCT04020913
NCT02973061
Lead Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions